Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ACTRN12626001130358) titled 'A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of GV-100 (Part3)' on Sept. 10.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Open (masking not used)
Primary Sponsor: Gilva Therapeutics, INC.
Condition:
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Renal and Urogenital - Kidney disease
Intervention:
Part 3: Food Effect (FE)
Participants will be administered one selected dose of GV-100 on Day 1 (treatment period 1) and on Day 8 (...